Infratil lifted FY27 operating EBITDAF guidance after a 28% first-half increase, led by data centres, renewables and One NZ. But the growth came with a NZ$247.8 million loss attributable to shareholders, a NZ$256 million incentive-fee provision and a sharp increase in capital spending.
- Proportionate operational EBITDAF rose 28% to NZ$711 million
- FY27 guidance lifted to NZ$1.37 billion-NZ$1.44 billion
- CDC EBITDAF rose 84% to A$339 million
- Proportionate capital expenditure nearly doubled to NZ$2.1 billion
- Interim dividend increased to 7.4 cents per share
Operating growth outpaces reported profit
Infratil Limited (NZX:IFT, ASX:IFT) is earning more from its operating portfolio while reporting less profit on the statutory line. Proportionate operational EBITDAF rose 28% to NZ$711 million in the six months ended 30 September 2026, prompting the infrastructure investor to lift FY27 guidance to NZ$1.37 billion-NZ$1.44 billion.
The catch was a NZ$256 million provision for international portfolio incentive fees, largely reflecting the higher valuation of data-centre operator CDC. Infratil reported a net loss attributable to shareholders of NZ$247.8 million, compared with a restated NZ$572.8 million surplus in the prior corresponding period. The group net loss was NZ$233.6 million.
That accounting charge does not erase the operational improvement, but it makes the headline result harder to read. Infratil’s preferred EBITDAF measure excludes incentive fees, valuation movements and other items, and is not an NZ IFRS measure. The half-year numbers therefore present two different stories: stronger underlying portfolio earnings and a statutory result weighed down by valuation-linked costs.
CDC drives the data-centre earnings surge
CDC Data Centres supplied the clearest evidence of the growth thesis. Its first-half EBITDAF rose 84% to A$339 million, with 350MW of capacity generating revenue at 30 September. Contracted capacity increased by 625MW during the half to 1.1GW, while another 810MW was under construction.
When fully deployed, that contracted capacity is expected to produce annualised EBITDAF of A$2.2 billion by the end of FY29. CDC has also raised its FY27 EBITDAF guidance to A$730 million-A$770 million and increased expected capital expenditure, excluding land, to A$4.0 billion-A$4.4 billion. The first building at its Laverton campus began operating in October.
The valuation uplift behind the incentive-fee provision was not entirely unexpected: CDC valuation expansion had already lifted Infratil’s assessment of the data-centre platform earlier this year. The latest presentation values Infratil’s share of CDC at NZ$11.35 billion, up from NZ$8.93 billion at March.
Renewables add scale and capital intensity
Longroad Energy also moved the earnings engine forward, increasing EBITDAF 10% to US$91 million as its operating renewable capacity reached 4.2GW. Almost 600MW of projects entered operation during the half, while 1.6GW was under construction at period-end. Longroad is targeting more than 14GW of operating or in-construction capacity by the end of 2029 and is assessing an initial 5GW of potential data-centre opportunities around its renewable assets.
That expansion is consuming capital at a faster rate. Infratil’s proportionate capital expenditure rose 98% to NZ$2.143 billion, driven principally by CDC and Longroad. Group FY27 capital-expenditure guidance has consequently increased to NZ$4.15 billion-NZ$4.45 billion, up from NZ$3.8 billion-NZ$4.4 billion.
Infratil’s earlier AI infrastructure growth strategy has now been narrowed around CDC, Longroad and adjacent opportunities rather than a broad search for a new large investment sector. The company says it is also exploring a 250MW data-centre development with Contact Energy in Stratford, while smaller renewable platforms continue to require development spending.
Portfolio resilience meets selective pressure
One NZ delivered a 10% EBITDAF increase to NZ$325 million, helped by 25,000 additional postpaid mobile connections and a one-off intellectual-property sale. Wellington Airport held EBITDAF broadly flat at NZ$66 million despite lower passenger numbers. The healthcare portfolio was less forgiving: Qscan EBITDAF fell A$4 million to A$39 million, leading to a reduction in FY27 guidance to A$75 million-A$85 million.
Portfolio asset value increased 8% from March to NZ$22.3 billion, while net portfolio asset value after estimated fees rose 10% to NZ$17.94 per share. Infratil had NZ$1.4 billion of available liquidity and a 14.2% loan-to-value ratio at 30 September, although the growth programme is plainly not cheap. The company invested NZ$409.5 million directly into portfolio businesses during the half and says more than NZ$1 billion of potential divestments could support the medium-term funding effort.
The board approved a partially imputed interim dividend of 7.4 cents per share, up from 7.25 cents. The distribution is a modest increase, but it sits alongside a reported loss, heavier borrowing requirements and a sizeable fee provision that remains linked to year-end valuations.
Bottom Line?
The next test is whether CDC and Longroad can convert their contracted build-out into cash earnings quickly enough to justify the capital burden and valuation-linked fees.
Questions in the middle?
- How much of the NZ$256 million incentive-fee provision will ultimately be payable after full-year valuations?
- Can CDC deliver its expanded construction programme without further increases in capital intensity or timing risk?
- Will proposed divestments and portfolio-company distributions keep pace with Infratil’s higher investment commitments and dividend policy?
Sources
- 2. Infratil FY27 Interim Results Presentation
- 3. Infratil FY27 Interim Report (including Infratil Group FY27 Interim Financial Statements)
- 1. Interim results for the period ended 30 September 2026
- 6. NZX Results Announcement - HY27
- 4. Detailed Financial Information & Operating Metrics - September 2026
- 5. Infratil Parent FY2027 Interim Financial Statements